These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Maternal serum placental growth factor (PlGF) isoforms 1 and 2 at 11-13 weeks' gestation in normal and pathological pregnancies. Nucci M; Poon LC; Demirdjian G; Darbouret B; Nicolaides KH Fetal Diagn Ther; 2014; 36(2):106-16. PubMed ID: 24457972 [TBL] [Abstract][Full Text] [Related]
24. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Akolekar R; Syngelaki A; Poon L; Wright D; Nicolaides KH Fetal Diagn Ther; 2013; 33(1):8-15. PubMed ID: 22906914 [TBL] [Abstract][Full Text] [Related]
25. Maternal plasma soluble fms-like tyrosine kinase-1 and free vascular endothelial growth factor at 11 to 13 weeks of gestation in preeclampsia. Akolekar R; de Cruz J; Foidart JM; Munaut C; Nicolaides KH Prenat Diagn; 2010 Mar; 30(3):191-7. PubMed ID: 20101671 [TBL] [Abstract][Full Text] [Related]
26. First trimester placental retinol-binding protein 4 (RBP4) and pregnancy-associated placental protein A (PAPP-A) in the prediction of early-onset severe pre-eclampsia. Yliniemi A; Nurkkala MM; Kopman S; Korpimaki T; Kouru H; Ryynanen M; Marttala J Metabolism; 2015 Apr; 64(4):521-6. PubMed ID: 25633269 [TBL] [Abstract][Full Text] [Related]
27. First trimester screening for intra-uterine growth restriction and early-onset pre-eclampsia. Vandenberghe G; Mensink I; Twisk JW; Blankenstein MA; Heijboer AC; van Vugt JM Prenat Diagn; 2011 Oct; 31(10):955-61. PubMed ID: 21717483 [TBL] [Abstract][Full Text] [Related]
28. Hypertensive disorders in pregnancy: combined screening by uterine artery Doppler, blood pressure and serum PAPP-A at 11-13 weeks. Poon LC; Stratieva V; Piras S; Piri S; Nicolaides KH Prenat Diagn; 2010 Mar; 30(3):216-23. PubMed ID: 20108221 [TBL] [Abstract][Full Text] [Related]
29. Second- and third-trimester serum levels of placental proteins in preeclampsia and small-for-gestational age pregnancies. Bersinger NA; Ødegård RA Acta Obstet Gynecol Scand; 2004 Jan; 83(1):37-45. PubMed ID: 14678084 [TBL] [Abstract][Full Text] [Related]
30. First-trimester maternal serum PP-13, PAPP-A and second-trimester uterine artery Doppler pulsatility index as markers of pre-eclampsia. Spencer K; Cowans NJ; Chefetz I; Tal J; Meiri H Ultrasound Obstet Gynecol; 2007 Feb; 29(2):128-34. PubMed ID: 17149788 [TBL] [Abstract][Full Text] [Related]
31. Prediction of pre-eclampsia by uterine artery Doppler ultrasonography and maternal serum pregnancy-associated plasma protein-A, free beta-human chorionic gonadotropin, activin A and inhibin A at 22 + 0 to 24 + 6 weeks' gestation. Spencer K; Yu CK; Savvidou M; Papageorghiou AT; Nicolaides KH Ultrasound Obstet Gynecol; 2006 Jun; 27(6):658-63. PubMed ID: 16493628 [TBL] [Abstract][Full Text] [Related]
33. Maternal serum placental growth factor isoforms 1 and 2 at 11-13, 20-24 and 30-34 weeks' gestation in late-onset pre-eclampsia and small for gestational age neonates. Nucci M; Poon LC; Demirdjian G; Darbouret B; Nicolaides KH Fetal Diagn Ther; 2014; 35(4):249-57. PubMed ID: 24642536 [TBL] [Abstract][Full Text] [Related]
34. Maternal thyroid function at 11 to 13 weeks of gestation and subsequent development of preeclampsia. Ashoor G; Maiz N; Rotas M; Kametas NA; Nicolaides KH Prenat Diagn; 2010 Nov; 30(11):1032-8. PubMed ID: 20865794 [TBL] [Abstract][Full Text] [Related]
35. Free leptin index and PAPP-A: a first trimester maternal serum screening test for pre-eclampsia. Hedley PL; Placing S; Wøjdemann K; Carlsen AL; Shalmi AC; Sundberg K; Tabor A; Christiansen M Prenat Diagn; 2010 Feb; 30(2):103-9. PubMed ID: 20013873 [TBL] [Abstract][Full Text] [Related]
36. Increased human placental growth hormone at midtrimester pregnancies may be an index of intrauterine growth retardation related to preeclampsia. Papadopoulou E; Sifakis S; Giahnakis E; Fragouli Y; Karkavitsas N; Koumantakis E; Kalmanti M Growth Horm IGF Res; 2006; 16(5-6):290-6. PubMed ID: 16996762 [TBL] [Abstract][Full Text] [Related]
37. Competing risks model in screening for preeclampsia by biophysical and biochemical markers at 30-33 weeks' gestation. Garcia-Tizon Larroca S; Tayyar A; Poon LC; Wright D; Nicolaides KH Fetal Diagn Ther; 2014; 36(1):9-17. PubMed ID: 24902880 [TBL] [Abstract][Full Text] [Related]
38. Fetal fraction of cell free DNA in screening for hypertensive disorders at 11-13 weeks. Sapantzoglou I; Gallardo Arozena M; Dragoi V; Akolekar R; Nicolaides KH; Syngelaki A J Matern Fetal Neonatal Med; 2022 Dec; 35(25):5363-5368. PubMed ID: 33517808 [TBL] [Abstract][Full Text] [Related]